MTHFD1

methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1, the group of Minor histocompatibility antigens

Basic information

Region (hg38): 14:64388031-64463457

Previous symbols: [ "MTHFC", "MTHFD" ]

Links

ENSG00000100714NCBI:4522OMIM:172460HGNC:7432Uniprot:P11586AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemiaARAllergy/Immunology/Infectious; Audiologic/Otolaryngologic; BiochemicalIndividuals have been described as presenting with severe and recurrent infections, as well as other sequelae, such as renal disease, and medical management (with folate and hydroxycobalamin) has been described as beneficial; In addition to folate and hydroxycobalamin treatment, antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial; Related to hearing deificits, early recognition and treatment of hearing impairment may improve outcomes, including speech and language developmentAllergy/Immunology/Infectious; Audiologic/Otolaryngologic; Biochemical; Hematologic; Neurologic; Renal23296427; 25633902; 27707659

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the MTHFD1 gene.

  • not provided (9 variants)
  • Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the MTHFD1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
118
clinvar
4
clinvar
123
missense
3
clinvar
177
clinvar
6
clinvar
4
clinvar
190
nonsense
6
clinvar
4
clinvar
10
start loss
0
frameshift
3
clinvar
1
clinvar
1
clinvar
5
inframe indel
0
splice donor/acceptor (+/-2bp)
7
clinvar
7
splice region
14
23
2
39
non coding
5
clinvar
78
clinvar
14
clinvar
97
Total 9 15 184 202 22

Highest pathogenic variant AF is 0.0000131

Variants in MTHFD1

This is a list of pathogenic ClinVar variants found in the MTHFD1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
14-64388445-C-T Benign (Dec 09, 2023)1590480
14-64388451-C-A Uncertain significance (Nov 03, 2021)1319857
14-64388456-A-G Uncertain significance (Feb 25, 2022)2103665
14-64388457-G-A Likely benign (Mar 20, 2023)2775991
14-64388481-CATT-C Likely benign (Aug 08, 2023)1642866
14-64388482-ATTG-A Likely benign (Nov 23, 2022)2794471
14-64400804-C-T MTHFD1-related disorder Likely benign (Jan 31, 2024)791428
14-64400805-G-A Likely benign (Oct 15, 2023)1610331
14-64400819-A-G Uncertain significance (Jul 11, 2021)1351536
14-64400855-C-T Uncertain significance (May 13, 2021)1480427
14-64400860-C-T Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia;Neural tube defects, folate-sensitive Uncertain significance (Mar 30, 2021)992516
14-64400861-G-A Inborn genetic diseases Uncertain significance (Nov 03, 2023)2069550
14-64400871-A-G Uncertain significance (Oct 19, 2022)1948219
14-64400874-A-G Likely benign (Feb 25, 2023)2968514
14-64400885-G-A Likely benign (Sep 21, 2022)1966611
14-64400890-T-C Likely benign (Jul 09, 2023)2797638
14-64411072-A-G Likely benign (Jul 19, 2023)1629925
14-64411078-T-C Likely benign (Apr 09, 2023)2813162
14-64411081-T-C Likely benign (May 11, 2022)1931774
14-64411098-C-T Likely benign (Oct 13, 2023)2421605
14-64411109-C-T Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia • Severe combined immunodeficiency disease Pathogenic/Likely pathogenic (Jan 01, 2024)446306
14-64411114-CTT-C Pathogenic (Nov 14, 2023)2813712
14-64411115-T-C Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia Likely pathogenic (Oct 15, 2018)446309
14-64411124-A-G Inborn genetic diseases Uncertain significance (Aug 12, 2021)2243940
14-64411151-T-TA Likely benign (Mar 14, 2023)1113442

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
MTHFD1protein_codingprotein_codingENST00000216605 2771974
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.004460.9961256950531257480.000211
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.684055120.7910.00002936110
Missense in Polyphen128205.230.623682472
Synonymous-0.1721971941.020.00001231871
Loss of Function4.621448.80.2870.00000249601

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0003650.000366
Ashkenazi Jewish0.0005960.000595
East Asian0.0002720.000272
Finnish0.0003700.000370
European (Non-Finnish)0.0002110.000211
Middle Eastern0.0002720.000272
South Asian0.00006530.0000653
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Disease
DISEASE: Neural tube defects, folate-sensitive (NTDFS) [MIM:601634]: The most common NTDs are open spina bifida (myelomeningocele) and anencephaly. {ECO:0000269|PubMed:12384833, ECO:0000269|PubMed:16552426, ECO:0000269|PubMed:9611072}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:17000706}. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry.; DISEASE: Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia (CIMAH) [MIM:617780]: An autosomal recessive disorder due to an inborn error of folate metabolism. Variable clinical manifestations include hemolytic uremic syndrome, macrocytosis, epilepsy, hearing loss, retinopathy, mild mental retardation, and lymphopenia. {ECO:0000269|PubMed:21813566, ECO:0000269|PubMed:25633902, ECO:0000269|PubMed:27707659}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Antimetabolite Pathway - Folate Cycle, Pharmacodynamics;One carbon pool by folate - Homo sapiens (human);Methotrexate Pathway (Cancer Cell), Pharmacodynamics;Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics;Folate malabsorption, hereditary;Methylenetetrahydrofolate Reductase Deficiency (MTHFRD);Methotrexate Action Pathway;Folate Metabolism;Folate Metabolism;One Carbon Metabolism;Trans-sulfuration and one carbon metabolism;folate polyglutamylation;Folate metabolism;Metabolism;folate transformations I;Metabolism of folate and pterines;histidine degradation;Metabolism of water-soluble vitamins and cofactors;Metabolism of vitamins and cofactors;Vitamin B9 (folate) metabolism;tetrahydrofolate salvage from 5,10-methenyltetrahydrofolate (Consensus)

Recessive Scores

pRec
0.210

Intolerance Scores

loftool
0.790
rvis_EVS
0.38
rvis_percentile_EVS
75.63

Haploinsufficiency Scores

pHI
0.780
hipred
Y
hipred_score
0.793
ghis
0.517

Essentials

essential_gene_CRISPR
E
essential_gene_CRISPR2
E
essential_gene_gene_trap
E
gene_indispensability_pred
E
gene_indispensability_score
0.553

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumHigh
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Mthfd1
Phenotype
immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype;

Gene ontology

Biological process
histidine biosynthetic process;neutrophil homeostasis;neural tube closure;purine nucleotide biosynthetic process;methionine metabolic process;one-carbon metabolic process;heart development;serine family amino acid metabolic process;serine family amino acid biosynthetic process;methionine biosynthetic process;purine nucleobase biosynthetic process;10-formyltetrahydrofolate biosynthetic process;transsulfuration;tetrahydrofolate interconversion;folic acid metabolic process;embryonic neurocranium morphogenesis;embryonic viscerocranium morphogenesis;oxidation-reduction process;somite development
Cellular component
cytoplasm;mitochondrion;cytosol;membrane;extracellular exosome
Molecular function
formate-tetrahydrofolate ligase activity;methenyltetrahydrofolate cyclohydrolase activity;methylenetetrahydrofolate dehydrogenase [NAD(P)+] activity;methylenetetrahydrofolate dehydrogenase (NAD+) activity;methylenetetrahydrofolate dehydrogenase (NADP+) activity;protein binding;ATP binding